Highlights
The following points summarize the core clinical findings regarding the use of direct-acting antivirals (DAAs) in managing hepatitis C virus (HCV)-associated indolent lymphomas: 1. Prospective trials consistently demonstrate a 100% sustained virologic response (SVR) rate in patients treated with DAAs. 2. Hematologic response rates (ORR) range from 45% to 67%, with complete responses occurring in approximately 20% to 67% of cases without the need for traditional chemotherapy. 3. Long-term follow-up from the BArT study indicates a 6-year progression-free survival (PFS) of 66%, with a remarkable finding of zero relapses among patients who achieved a complete response. 4. These findings provide definitive evidence of a causative link between HCV and lymphomagenesis, supporting the use of DAAs as a primary, first-line therapy for this patient population.
